Naume, Bjørn <br/><br/>
Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Dec 2014 
 - 3848-57 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Webcast 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2014.56.9327  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Phytogenic--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bone Marrow Cells--chemistry<br/>Breast Neoplasms--chemistry<br/>Chemotherapy, Adjuvant<br/>Chi-Square Distribution<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Docetaxel<br/>Drug Administration Schedule<br/>Epirubicin--administration & dosage<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Immunohistochemistry<br/>Infusions, Intravenous<br/>Kaplan-Meier Estimate<br/>Keratins--analysis<br/>Ki-67 Antigen--analysis<br/>Middle Aged<br/>Neoplastic Cells, Circulating--chemistry<br/>Norway<br/>Predictive Value of Tests<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Retreatment<br/>Risk Factors<br/>Taxoids--administration & dosage<br/>Time Factors<br/>Treatment Failure